Mohamed Eissa
Research Subjects
Research Interests
Mohamed Eissa has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Alaa A. Omran
KSA, Abha, 61412, P.O. Box 641
2 shared publicationsNadia ElMenshawy
Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, Egypt
2 shared publicationsAbdallah Salem Abdelazem
KSA, Abha, 61412, P.O. Box 641
1 shared publication- Abdulrahman Theyab
Department of Laboratory & Blood Bank, Security Forces Hospital, P.O. Box 14799, Mecca 21955, Saudi Arabia
1 shared publication Ahmed Darwish
Hematology Pediatric Medicine, Mansoura Children Hospital
1 shared publicationAlbatool M. Al-Nahari
F Clinical Laboratory Science Department, College of Applied Medical Science , Abha , Kingdom of Saudi Arabia
1 shared publication
Latest Publications
- 13 August 2024
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 45 (5) , 481-491
Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma
Multiple myeloma (MM) is a prevalent yet incurable hematologic malignancy. Despite the proven efficacy of proteasome inhibitors in treating MM, resistance to Bortezomib-based treatments persists in a subset of patients. This case control study explores the potential of circulating endothelial progenitor cells (EPCs) as biomarkers for predicting response to Proteasome Inhibitor based therapy combined with Dexamethasone in MM patients. This study was conducted on 105 MM patients receiving bortezomib plus dexamethasone therapy and 90 healthy individuals as a control group. Utilizing 8-color multi-parameter flow cytometry, we assessed the levels of circulating EPCs, identified through CD34 FITC and CD309 PE markers at diagnosis and after one treatment cycle (4 weeks). Our findings revealed that patients exhibiting poor response to therapy showed significantly higher CD34/CD309 values than those with a good response (p < 0.001). The delineation of response based on CD34/CD309 expression was established with a cutoff ≤ 0.9 for percentage (yielding 100% sensitivity and 94.1% specificity) and ≤ 12.5 for absolute value (also with 100% sensitivity and 94.1% specificity). These results underscore the potential of EPC population levels, as quantified by CD34/CD309, to serve as a predictive biomarker for immunomodulatory treatment in MM patients undergoing Proteasome Inhibitor and Dexamethasone therapy.
- 13 August 2024
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 45 (5) , 481-491
Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma
Multiple myeloma (MM) is a prevalent yet incurable hematologic malignancy. Despite the proven efficacy of proteasome inhibitors in treating MM, resistance to Bortezomib-based treatments persists in a subset of patients. This case control study explores the potential of circulating endothelial progenitor cells (EPCs) as biomarkers for predicting response to Proteasome Inhibitor based therapy combined with Dexamethasone in MM patients. This study was conducted on 105 MM patients receiving bortezomib plus dexamethasone therapy and 90 healthy individuals as a control group. Utilizing 8-color multi-parameter flow cytometry, we assessed the levels of circulating EPCs, identified through CD34 FITC and CD309 PE markers at diagnosis and after one treatment cycle (4 weeks). Our findings revealed that patients exhibiting poor response to therapy showed significantly higher CD34/CD309 values than those with a good response (p < 0.001). The delineation of response based on CD34/CD309 expression was established with a cutoff ≤ 0.9 for percentage (yielding 100% sensitivity and 94.1% specificity) and ≤ 12.5 for absolute value (also with 100% sensitivity and 94.1% specificity). These results underscore the potential of EPC population levels, as quantified by CD34/CD309, to serve as a predictive biomarker for immunomodulatory treatment in MM patients undergoing Proteasome Inhibitor and Dexamethasone therapy.
- 22 March 2023
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 44 (4) , 326-337
CD44, CD90 and CD96 expression in immune thrombocytopenia purpura (ITP) patients
Studying the expression of hematopoietic stem cell markers from different sources might be useful in understanding stem cell biology in different niche conditions. The study aimed to assess the difference in cell surface markers (CD44, CD90, CD96) on hematopoietic stem cells in three different niche conditions; umbilical cord blood (UCB), normal bone marrow (NBM) and bone marrow samples from idiopathic (immune) thrombocytopenic purpura (IBM). This study was conducted on 300 cases divided into three study groups; 100 umbilical cord blood units collected from mothers undergoing cesarian section in gynecology and obstetrics department, 100 bone marrow samples from idiopathic (immune) thrombocytopenic purpura patients collected from university children hospital and 100 normal bone marrow samples with no evidence of disease in bone marrow tissue. CD44 was significantly elevated in UCB and NBM groups compared to IBM group (<0.001). There was also a significant elevation of CD90 and CD96 in IBM group compared to NBM group and UCB (<0.001). CD90 and CD96 play a role in the pathogenesis of ITP disorder and could be applied as a targeted therapy to improve the outcome of this disease.
- 22 March 2023
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 44 (4) , 326-337
CD44, CD90 and CD96 expression in immune thrombocytopenia purpura (ITP) patients
Studying the expression of hematopoietic stem cell markers from different sources might be useful in understanding stem cell biology in different niche conditions. The study aimed to assess the difference in cell surface markers (CD44, CD90, CD96) on hematopoietic stem cells in three different niche conditions; umbilical cord blood (UCB), normal bone marrow (NBM) and bone marrow samples from idiopathic (immune) thrombocytopenic purpura (IBM). This study was conducted on 300 cases divided into three study groups; 100 umbilical cord blood units collected from mothers undergoing cesarian section in gynecology and obstetrics department, 100 bone marrow samples from idiopathic (immune) thrombocytopenic purpura patients collected from university children hospital and 100 normal bone marrow samples with no evidence of disease in bone marrow tissue. CD44 was significantly elevated in UCB and NBM groups compared to IBM group (<0.001). There was also a significant elevation of CD90 and CD96 in IBM group compared to NBM group and UCB (<0.001). CD90 and CD96 play a role in the pathogenesis of ITP disorder and could be applied as a targeted therapy to improve the outcome of this disease.
- Open Access
- 15 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14102
Assessment of RACGAP1 as a Prognostic and Immunological Biomarker in Multiple Human Tumors: A Multiomics Analysis
Several recent studies have pointed out that arc GTPase activating protein 1 (RACGAP1) is a putative oncogene in many human tumors. However, to date, no pan-cancer analysis has been performed to study the different aspects of this gene expression and behavior in tumor tissues. Here, we applied several bioinformatics tools to perform a comprehensive analysis for RACGAP1. First, we assessed the expression of RACGAP1 in several types of human tumors and tried to correlate that with the stage of the tumors analyzed. We then performed a survival analysis to study the correlation between RACGAP1 upregulation in tumors and the clinical outcome. Additionally, we investigated the mutation forms, the correlation with several immune cell infiltration, the phosphorylation status of the interested protein in normal and tumor tissues, and the potential molecular mechanisms of RACGAP1 in cancerous tissue. The results demonstrated that RACGAP1, a highly expressed gene across several types of tumors, correlated with a poor prognosis in several types of human cancers. Moreover, it was found that RACGAP1 affects the tumor immune microenvironment by influencing the infiltration level of several immune cells. Collectively, the current study provides a comprehensive overview of the oncogenic roles of RACGAP1, where our results nominate it as a potential prognostic biomarker and a target for antitumor therapy development.
- 15 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14102
Open AccessAssessment of RACGAP1 as a Prognostic and Immunological Biomarker in Multiple Human Tumors: A Multiomics Analysis
Several recent studies have pointed out that arc GTPase activating protein 1 (RACGAP1) is a putative oncogene in many human tumors. However, to date, no pan-cancer analysis has been performed to study the different aspects of this gene expression and behavior in tumor tissues. Here, we applied several bioinformatics tools to perform a comprehensive analysis for RACGAP1. First, we assessed the expression of RACGAP1 in several types of human tumors and tried to correlate that with the stage of the tumors analyzed. We then performed a survival analysis to study the correlation between RACGAP1 upregulation in tumors and the clinical outcome. Additionally, we investigated the mutation forms, the correlation with several immune cell infiltration, the phosphorylation status of the interested protein in normal and tumor tissues, and the potential molecular mechanisms of RACGAP1 in cancerous tissue. The results demonstrated that RACGAP1, a highly expressed gene across several types of tumors, correlated with a poor prognosis in several types of human cancers. Moreover, it was found that RACGAP1 affects the tumor immune microenvironment by influencing the infiltration level of several immune cells. Collectively, the current study provides a comprehensive overview of the oncogenic roles of RACGAP1, where our results nominate it as a potential prognostic biomarker and a target for antitumor therapy development.
- 1 April 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 87 (1) , 1293-1296
Impact of NQO1 C609T Polymorphism on The Outcome of Childhood Acute Lymphoblastic Leukemia from Zagazig University Hospital; Egypt
Background: The NAD (P) H: quinone oxidoreductase (NQO1) C609T polymorphism has been widely thought to be associated with the risk of acute leukemia. Objective: This case-control study aimed to assess the impact of NQO1 C609T gene polymorphism in childhood acute lymphoblastic leukemia (ALL). Patients and Method: The study was carried out on one hundred de novo ALL children and one hundred apparently healthy children. Routine genotyping of NQO1C609T gene polymorphism by PCR-RFLP was done for all subjects. Results: No statistically significant difference was observed between the patient group and control group as regards wild and polymorphic genotypes. However, there was a significant difference between ALL patients with wild and polymorphic genotypes regarding their immunophenotyping diagnosis (P=0.02) and FAB classification (P=0.01). There was also a significant difference between ALL patients with wild and polymorphic genotypes regarding their response to treatment. The complete remission in the wild genotype (CC) was 69.2% while in polymorphic genotypes (TT & CT) was 29.4% (P<0.05). Conclusion: The polymorphic genotype forms of the NQO1 C609T (CT and TT) are associated with decreased response to treatment.
- 1 April 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 87 (1) , 1293-1296
Impact of NQO1 C609T Polymorphism on The Outcome of Childhood Acute Lymphoblastic Leukemia from Zagazig University Hospital; Egypt
Background: The NAD (P) H: quinone oxidoreductase (NQO1) C609T polymorphism has been widely thought to be associated with the risk of acute leukemia. Objective: This case-control study aimed to assess the impact of NQO1 C609T gene polymorphism in childhood acute lymphoblastic leukemia (ALL). Patients and Method: The study was carried out on one hundred de novo ALL children and one hundred apparently healthy children. Routine genotyping of NQO1C609T gene polymorphism by PCR-RFLP was done for all subjects. Results: No statistically significant difference was observed between the patient group and control group as regards wild and polymorphic genotypes. However, there was a significant difference between ALL patients with wild and polymorphic genotypes regarding their immunophenotyping diagnosis (P=0.02) and FAB classification (P=0.01). There was also a significant difference between ALL patients with wild and polymorphic genotypes regarding their response to treatment. The complete remission in the wild genotype (CC) was 69.2% while in polymorphic genotypes (TT & CT) was 29.4% (P<0.05). Conclusion: The polymorphic genotype forms of the NQO1 C609T (CT and TT) are associated with decreased response to treatment.
- 1 October 2021
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 85 (2) , 4223-4226
Vitamin D Receptor Gene (Fok-I) Polymorphisms in Type 1 Diabetic Children; Case Study in Zagazig University Hospitals
Background: Many meta-analyses studied the association between vitamin D receptor (VDR) gene polymorphism and type 1 diabetes (T1DM) susceptibility. Objective: This study was designed to assess the role of VDR gene (FOK-I) polymorphisms in type 1 diabetic children from Zagazig University Hospitals in Egypt. Patients and Method: In this case-control study, the genotypes of VDR gene (FOK-I) polymorphisms were assessed in 180 type 1 diabetic children and 120 healthy matched age controls by PCR-RFLP analysis. Results: Ahigh statistical difference between patient and control regarding VDR gene (FOK-I) polymorphisms, where 44% of the patient group had heterozygous genotype (AG) compared to 8.3% in the control group. AG genotype has almost a higher risk nine times odds ratio (OR) = 8.8 than AA genotype in diabetic patients. There was a significant increase in the G allele in the patient group. Moreover, a significant association between (FOK-I) polymorphisms and T1DM complications was also observed. Conclusion: (AG) genotype of VDR gene (FOK-I) polymorphisms could be a risk factor for T1DM complications. So, VDR gene (FOK-I) polymorphisms should be performed with other genetic studies for early prediction, detection and prevention of microvascular complications of T1DM that adversely affect health-related quality of life of Egyptian children and burden the primary care units.
- 1 October 2021
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 85 (2) , 4223-4226
Vitamin D Receptor Gene (Fok-I) Polymorphisms in Type 1 Diabetic Children; Case Study in Zagazig University Hospitals
Background: Many meta-analyses studied the association between vitamin D receptor (VDR) gene polymorphism and type 1 diabetes (T1DM) susceptibility. Objective: This study was designed to assess the role of VDR gene (FOK-I) polymorphisms in type 1 diabetic children from Zagazig University Hospitals in Egypt. Patients and Method: In this case-control study, the genotypes of VDR gene (FOK-I) polymorphisms were assessed in 180 type 1 diabetic children and 120 healthy matched age controls by PCR-RFLP analysis. Results: Ahigh statistical difference between patient and control regarding VDR gene (FOK-I) polymorphisms, where 44% of the patient group had heterozygous genotype (AG) compared to 8.3% in the control group. AG genotype has almost a higher risk nine times odds ratio (OR) = 8.8 than AA genotype in diabetic patients. There was a significant increase in the G allele in the patient group. Moreover, a significant association between (FOK-I) polymorphisms and T1DM complications was also observed. Conclusion: (AG) genotype of VDR gene (FOK-I) polymorphisms could be a risk factor for T1DM complications. So, VDR gene (FOK-I) polymorphisms should be performed with other genetic studies for early prediction, detection and prevention of microvascular complications of T1DM that adversely affect health-related quality of life of Egyptian children and burden the primary care units.
- 1 October 2021
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 85 (2) , 3737-3741
The Predictive Value of Vanin-1 in Pediatric Immune Thrombocytopenia
Background: Immune thrombocytopenia (ITP) has oxidative stress-related pathway as one of its possible mechanisms. Vanin-1 (VNN1) is an oxidative stress sensitive sensor. Objective: The present study was conducted to assess the clinical significance of VNN1 in pediatric ITP patients. Patients and Methods: A total of 50 kids with ITP have been involved in this work; 25 newly diagnosed, 25 chronic patients with ITP more than 12 months (15 responders and 10 non responders to treatment) and 25 apparently healthy children. All groups had their serum VNN-1 levels checked using a two-antibody sandwich enzyme-linked immunosorbent test. Results: The serum VNN1 level was significantly higher in ITP group than control group (p˂0.001). The level of serum VNN1 was significantly very high in newly diagnosed ITP group (p˂0.001) in comparison to chronic responders and chronic non responders ITP groups. Moreover, there was a significant increase in serum VNN1 level in chronic non responders ITP group (p˂0.001) compared to chronic responders group. In newly diagnosed ITP group, both age (r=-0.62, p=0.006) and the platelet count (r=-0.46, p=0.01) had a significant negative connection with serum VNN1 level. A cut-off value lower than 0.6 ng/ml for serum VNN1 could be used to distinguish the chronic non-responders ITP from chronic responders patients with 100 percent specificity and 90 percent sensitivity. Conclusion: From our current results, it is hypothesized that high VNN1 level plays a role in the pathogenesis and progress of pediatric ITP.
- 1 October 2021
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 85 (2) , 3737-3741
The Predictive Value of Vanin-1 in Pediatric Immune Thrombocytopenia
Background: Immune thrombocytopenia (ITP) has oxidative stress-related pathway as one of its possible mechanisms. Vanin-1 (VNN1) is an oxidative stress sensitive sensor. Objective: The present study was conducted to assess the clinical significance of VNN1 in pediatric ITP patients. Patients and Methods: A total of 50 kids with ITP have been involved in this work; 25 newly diagnosed, 25 chronic patients with ITP more than 12 months (15 responders and 10 non responders to treatment) and 25 apparently healthy children. All groups had their serum VNN-1 levels checked using a two-antibody sandwich enzyme-linked immunosorbent test. Results: The serum VNN1 level was significantly higher in ITP group than control group (p˂0.001). The level of serum VNN1 was significantly very high in newly diagnosed ITP group (p˂0.001) in comparison to chronic responders and chronic non responders ITP groups. Moreover, there was a significant increase in serum VNN1 level in chronic non responders ITP group (p˂0.001) compared to chronic responders group. In newly diagnosed ITP group, both age (r=-0.62, p=0.006) and the platelet count (r=-0.46, p=0.01) had a significant negative connection with serum VNN1 level. A cut-off value lower than 0.6 ng/ml for serum VNN1 could be used to distinguish the chronic non-responders ITP from chronic responders patients with 100 percent specificity and 90 percent sensitivity. Conclusion: From our current results, it is hypothesized that high VNN1 level plays a role in the pathogenesis and progress of pediatric ITP.
- 25 August 2021
- Published by Taylor & Francis in Cancer Investigation
- Vol. 39 (9) , 777-782
Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients
Multiple myeloma is an incurable hematological malignancy. Currently, the use of proteasome inhibitors could be superior to chemotherapy-based regimen in the treatment of this disease. However, resistance to bortezomib combination therapy still occurs in some patients. So, this research work aims to assess CD69 and CD56 expression in these cases and their relation to the response to therapy. Immunophenotyping by 4-color multi-parameter flow cytometry was carried out on 98 multiple myeloma cases. Clonal plasma cells were gated by co-expression of CD38 with CD138 with low SSC, negative or dim CD45. Double negative CD69 and CD56 (47.9%) multiple myeloma cases were associated with high serum β2 microglobulin, creatinine, calcium and low serum albumin. There was also a significant correlation between the absence of these markers with osteolytic lesions and unfavorable cytogenetic t (4;14) (p < 0.001). Moreover, there was a highly significant correlation between CD69- and CD56- with non-response to bortezomib combination therapy in multiple myeloma patients (p < 0.0001). Regression analysis for the prediction of non- response to treatment in these cases using different prognostic indicators revealed that high serum β2 microglobulin, unfavorable cytogenetic, advanced stage, and low expression of CD69 and CD56 were poor predictors of non-response. CD69 in association with CD56 could be an independent prognostic factor in multiple myeloma cases. It could be used in the routine laboratory assessment for refining stratification and timely therapeutic decision for highly cost therapy in developing countries.
- 25 August 2021
- Published by Taylor & Francis in Cancer Investigation
- Vol. 39 (9) , 777-782
Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients
Multiple myeloma is an incurable hematological malignancy. Currently, the use of proteasome inhibitors could be superior to chemotherapy-based regimen in the treatment of this disease. However, resistance to bortezomib combination therapy still occurs in some patients. So, this research work aims to assess CD69 and CD56 expression in these cases and their relation to the response to therapy. Immunophenotyping by 4-color multi-parameter flow cytometry was carried out on 98 multiple myeloma cases. Clonal plasma cells were gated by co-expression of CD38 with CD138 with low SSC, negative or dim CD45. Double negative CD69 and CD56 (47.9%) multiple myeloma cases were associated with high serum β2 microglobulin, creatinine, calcium and low serum albumin. There was also a significant correlation between the absence of these markers with osteolytic lesions and unfavorable cytogenetic t (4;14) (p < 0.001). Moreover, there was a highly significant correlation between CD69- and CD56- with non-response to bortezomib combination therapy in multiple myeloma patients (p < 0.0001). Regression analysis for the prediction of non- response to treatment in these cases using different prognostic indicators revealed that high serum β2 microglobulin, unfavorable cytogenetic, advanced stage, and low expression of CD69 and CD56 were poor predictors of non-response. CD69 in association with CD56 could be an independent prognostic factor in multiple myeloma cases. It could be used in the routine laboratory assessment for refining stratification and timely therapeutic decision for highly cost therapy in developing countries.
- 4 July 2018
- Published by Taylor & Francis in Hemoglobin
- Vol. 42 (4) , 264-268
Awareness and Attitude of University Students About Screening and Testing for Hemoglobinopathies: Case Study of the Aseer Region, Saudi Arabia
Hemoglobinopathies can disturb a patient’s life style leading to community problems. Premarital screening is an important tool to control and minimize hemoglobinopathies. This study aimed to assess and improve the awareness and attitude of King Khalid University (KKU) [Abha, Kingdom of Saudi Arabia (KSA)] students in the Aseer Region, regarding hemoglobinopathies and the National Premarital Screening Programme (NPMS) in addition to screening for hemoglobin (Hb) variants of students who agreed to participate. This study was an interventional educational prospective study of electronic-lectures (e-lectures) that addressed some important issues of hemoglobinopathies and premarital screening. Six hundred and eleven students were interviewed during the academic year 2017/2018, using closed-ended questionnaires that distributed before and after intervention. Blood samples were taken from 114 students who agreed to check their Hb type by the D-10 Hemoglobin Testing System. The results revealed significant changes in knowledge and attitude of students toward hemoglobinopathies and premarital counseling after intervention. These results reflected the need for easily accessible and continuous health education programs for students to increase their awareness and attitude toward hemoglobinopathies. Laboratory results for 114 students revealed seven cases with microcytic hypochromic anemia (6.1%); they were all females. Blood screening for Hb variants revealed another two females (1.75%) with sickle cell trait (Hb AS). Electronic-health (E-health) is an efficient tool for improving the awareness and attitude of the community toward hemoglobinopathies. Screening blood tests for detection of hemoglobinopathies should be provided to young adults at an earlier stage (before marriage) to decrease the incidence of hereditary diseases in the community.
- 4 July 2018
- Published by Taylor & Francis in Hemoglobin
- Vol. 42 (4) , 264-268
Awareness and Attitude of University Students About Screening and Testing for Hemoglobinopathies: Case Study of the Aseer Region, Saudi Arabia
Hemoglobinopathies can disturb a patient’s life style leading to community problems. Premarital screening is an important tool to control and minimize hemoglobinopathies. This study aimed to assess and improve the awareness and attitude of King Khalid University (KKU) [Abha, Kingdom of Saudi Arabia (KSA)] students in the Aseer Region, regarding hemoglobinopathies and the National Premarital Screening Programme (NPMS) in addition to screening for hemoglobin (Hb) variants of students who agreed to participate. This study was an interventional educational prospective study of electronic-lectures (e-lectures) that addressed some important issues of hemoglobinopathies and premarital screening. Six hundred and eleven students were interviewed during the academic year 2017/2018, using closed-ended questionnaires that distributed before and after intervention. Blood samples were taken from 114 students who agreed to check their Hb type by the D-10 Hemoglobin Testing System. The results revealed significant changes in knowledge and attitude of students toward hemoglobinopathies and premarital counseling after intervention. These results reflected the need for easily accessible and continuous health education programs for students to increase their awareness and attitude toward hemoglobinopathies. Laboratory results for 114 students revealed seven cases with microcytic hypochromic anemia (6.1%); they were all females. Blood screening for Hb variants revealed another two females (1.75%) with sickle cell trait (Hb AS). Electronic-health (E-health) is an efficient tool for improving the awareness and attitude of the community toward hemoglobinopathies. Screening blood tests for detection of hemoglobinopathies should be provided to young adults at an earlier stage (before marriage) to decrease the incidence of hereditary diseases in the community.